| 1 |
Partly verified |
Full text not readStored summary read |
N01 · Evidence conditionWhich acetaminophen comparison is being considered?Required |
The selected original claim is analgesic efficacy equivalent to acetaminophen. The existing explanation records that the early trial was not designed to establish equivalence or noninferiority, separately from analgesia versus placebo. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between the existing equivalence question and analgesia versus placebo |
Material needed: The original active-comparator design, denominators, effect, CI and prespecified margin are needed. This sheet is not counted as a new independent study. This records needed materials; no new research was executed. |
| 2 |
Partly verified |
Full text not readStored summary read |
N02 · Evidence conditionDoes no difference establish equivalence or noninferiority?Required |
The preserved account explains that no difference from acetaminophen did not establish equivalence. No new conclusion of equal or interchangeable treatments is made. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria |
Material needed: The prespecified clinical margin, effect of interest, test direction, relevant CI and analysis plan are needed. Nonsignificance is not converted into proof of equivalence. This records needed materials; no new research was executed. |
| 3 |
Partly verified |
Full text not readStored summary read |
N03 · Evidence conditionAre the exact active-comparator effect, CI and P known?Required |
The early result is a narrative of no difference from acetaminophen. Its exact effect, CI, P and test are absent from the summary; P<.01 concerns pain reduction versus placebo. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Estimate and precision of the direct comparison with acetaminophen |
Material needed: Original active-comparator effect, CI, scale, time, denominators, testing and multiplicity materials are needed. The placebo P is not copied as the active-comparator P. This records needed materials; no new research was executed. |
| 4 |
Partly verified |
Full text not readStored summary read |
N04 · Evidence conditionIs a signal versus placebo direct evidence of equivalence?Required |
The early trial's pain reduction versus placebo, P<.01, is retained. This signal is not converted into a direct estimate of equivalence to acetaminophen or a prespecified equivalence trial. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between effects versus placebo and versus an active comparator |
Material needed: The active-comparator effect, CI, original design and prespecified margin at the same time and analysis are needed. This records needed materials; no new research was executed. |
| 5 |
Partly verified |
Full text not readStored summary read |
N05 · Evidence conditionAre 41 participants and 164 attacks the same denominator?Required |
R01 is a repeated-attack crossover trial with 41 participants and 164 headache attacks. The 164 attacks are not labeled as participants or added as independent participants. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Participants, attacks, treatment periods and units of analysis |
Material needed: Treatments and attacks per participant, allocation sequence, periods, endpoint-specific analysis denominators and repeated-data methods are needed. No new mean attack count is calculated. This records needed materials; no new research was executed. |
| 6 |
Partly verified |
Full text not readStored summary read |
N06 · Evidence conditionAre crossover correlation, carryover and period effects verified?Required |
The original design is a randomized double-blind repeated-attack crossover trial. Its label alone does not verify independence of attacks, washout, or handling of period and sequence effects. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Treatment sequence, washout, carryover and within-participant correlation |
Material needed: Original allocation sequence, periods, washout, carryover tests, paired data, within-participant correlation and missing-data methods are needed. No independent parallel-group calculation is performed. This records needed materials; no new research was executed. |
| 7 |
Unverified |
Full text not readStored summary read |
N07 · Evidence conditionAre acetaminophen dose, formulation and concurrent-care conditions known?Required |
The preserved account records comparison with placebo or acetaminophen. The summary lacks exact acetaminophen dose, formulation, timing, concurrent care and rescue-medication conditions. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Arm-specific exposure conditions for active, topical and placebo comparisons |
Material needed: Original arm-specific drugs, formulations, concurrent care, rescue medication, exposure and comparator conditions are needed. No new dose, use or administration guidance is created. This records needed materials; no new research was executed. |
| 8 |
Partly verified |
Full text not readStored summary read |
N08 · Evidence conditionWhich 10% topical formulation was compared?Required |
The parent account's topical 10% peppermint-oil and 90% ethanol solution is retained. Inhalation, oral enteric capsules and migraine involve different routes or populations; concentration is not converted into absorbed dose. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
The specific topical solution of 10% peppermint oil and 90% ethanol |
Material needed: Original product, manufacture, composition, exposure, use records and comparator-vehicle details are needed. Formulations are distinguished by report, without new procedures or treatment guidance. This records needed materials; no new research was executed. |
| 9 |
Partly verified |
Full text not readStored summary read |
N09 · Evidence conditionAre tension-type headache and migraine populations distinguished?Required |
The original population has acute tension-type headache. The early 41 participants and 164 attacks do not replace detailed diagnosis or eligibility; the context excluding inhalation, enteric capsules and migraine is retained. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Eligibility and attack characteristics in acute tension-type headache |
Material needed: Original diagnostic criteria, frequency, severity, baseline pain, exclusions, comorbidity and recruitment information are needed. Findings are not extended to other headaches or populations. This records needed materials; no new research was executed. |
| 10 |
Partly verified |
Full text not readStored summary read |
N10 · Evidence conditionAre pain after 15 minutes and response at 120 minutes the same endpoint?Required |
The early comparison concerns pain intensity from 15 minutes and an active comparator. The later first primary endpoint is VPRS response at 120 minutes, followed by VAS-SPID; these are not treated as the same scale, time or responder definition. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Timing and scales of early pain intensity and later VPRS response |
Material needed: Each scale, response definition, baseline and follow-up, denominators, original analysis and prespecified hierarchy are needed. Times and scales are not converted or results merged. This records needed materials; no new research was executed. |
| 11 |
Partly verified |
Full text not readStored summary read |
N11 · Evidence conditionWhat are the later trial's starting size and analysis denominators?Required |
The later trial records 209 started, 189 in FAS and 94 versus 95. The 37/94 versus 28/95 comparison concerns response at 120 minutes; the starting count does not replace FAS denominators or event totals. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between 209 started, 189 in FAS and 94 versus 95 |
Material needed: Allocation, treatment and completion flow, FAS definition, exclusion and missingness reasons, and original arm-specific analysis populations are needed. No new count difference, response rate or effect is calculated. This records needed materials; no new research was executed. |
| 12 |
Partly verified |
Full text not readStored summary read |
N12 · Evidence conditionIs failure of the later first primary endpoint's threshold retained?Required |
The later response at 120 minutes, 37/94 versus 28/95, retains failure of the prespecified one-sided .025 threshold. A benefit direction is not converted into passing the threshold or an exactly 0 effect. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Prespecified one-sided Fisher .025 threshold and hierarchical gate |
Material needed: Original registered results, prespecified plan, testing, denominators, direct effect and CI are needed. The original criterion is not replaced by a different two-sided .05 criterion. This records needed materials; no new research was executed. |
| 13 |
Partly verified |
Full text not readStored summary read |
N13 · Evidence conditionWas two-sided Fisher P≈.101 calculated in this work?Required |
The preserved result explicitly attributes two-sided Fisher P≈.101 to a historical Codex recalculation. The value and attribution are retained without presenting it as a current calculation or the original prespecified one-sided result. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between the historical Codex calculation from counts and original trial results |
Material needed: Original results and analysis plan, and a separate record of the historical calculation, are needed. No statistical recalculation or new effect or CI is produced here. This records needed materials; no new research was executed. |
| 14 |
Partly verified |
Full text not readStored summary read |
N14 · Evidence conditionIs VAS-SPID treated as confirmatory after the first primary endpoint failed?Required |
The parent account treats the second VAS-SPID endpoint as exploratory after the first primary endpoint failed. The parent's secondary-result indicator is not converted into current confirmatory analgesia or successful equivalence. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Exploratory context of the hierarchically second endpoint |
Material needed: The prespecified hierarchy, original second-endpoint result, CI, denominators, adjustment and testing procedures are needed. Unread values are not filled in. This records needed materials; no new research was executed. |
| 15 |
Partly verified |
Full text not readStored summary read |
N15 · Evidence conditionIs the later placebo-controlled trial an active-comparator equivalence trial?Required |
The later report is a registered placebo-controlled phase 4 trial. Its context as follow-up of a topical product is retained without turning it into a direct trial of equivalence to acetaminophen. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between the later placebo comparison and early acetaminophen comparison |
Material needed: Prespecified active-comparator design, margin and CI directly addressing the selected question are needed. Results against a different comparator do not replace them. This records needed materials; no new research was executed. |
| 16 |
Unverified |
Full text not readStored summary read |
N16 · Evidence conditionAre the prespecified equivalence margin and power known?Required |
The existing explanation says that the early trial was not designed to establish equivalence or noninferiority. Original clinical margins, power and relevant analysis populations are absent; no difference alone does not certify substitutability. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Patient-important margin, sample-size plan, ITT and PP |
Material needed: The basis for a prespecified clinical margin, sample-size plan, direct CI, ITT and PP definitions and sensitivity analyses are needed. No new margin or sample size is calculated. This records needed materials; no new research was executed. |
| 17 |
Partly verified |
Full text not readStored summary read |
N17 · Evidence conditionDoes rapid pain relief establish sustained recovery or recurrence prevention?Required |
The parent's scope is pain relief in acute tension-type headache. An early rapid signal is not converted into direct confirmation of sustained recovery, causal treatment, long-term prevention or replacement of acetaminophen. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Acute pain and response versus persistence, recurrence and rescue-medication outcomes |
Material needed: Original definitions, denominators, effects and CIs for complete pain freedom, persistence, recurrence, rescue medication and patient-important outcomes are needed. This records needed materials; no new research was executed. |
| 18 |
Partly verified |
Full text not readStored summary read |
N18 · Evidence conditionAre early positive findings and later failure both retained?Required |
The parent account addresses both a small early signal and failure of the larger registered trial's first primary endpoint, prioritizing the later failure. Both results are retained and distinguished from directness for equivalence. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Early and later reports, and directness for the equivalence question |
Material needed: Original material distinguishing products, populations, times, comparators, denominators, prespecified endpoints, effects and CIs in the two reports is needed. This records needed materials; no new research was executed. |
| 19 |
Partly verified |
Full text not readStored summary read |
N19 · Evidence conditionAre funding, products, authorship and design or analysis involvement separated?Required |
Specific early funding and manufacturer involvement are unverified; the later trial was sponsored by Cassella-med GmbH. The parent's I0 and weak-independence explanation are not converted into new category-specific conclusions of absence or causation. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Independence assessed by specific support and involvement categories |
Material needed: Separate material on research funding, product provision, author affiliations and involvement in design, analysis and publication is needed. Sponsorship alone does not fill other categories. This records needed materials; no new research was executed. |
| 20 |
Partly verified |
Full text not readStored summary read |
N20 · Evidence conditionAre denominators and collection methods for skin and eye harms known?Supplementary |
The parent's safety wording concerns skin stinging, redness, eye injury and application boundaries for concentrated peppermint oil and ethanol. The summary lacks actual arm-specific harm counts, collection methods, denominators and exposure. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Topical harm events, exposure, routes and vulnerable groups |
Material needed: Harm collection, events and affected people, severity, timing, exposure, arm-specific denominators and actual inclusion of children, eyes or mucosa are needed. No new use or treatment guidance is created. This records needed materials; no new research was executed. |
| 21 |
Partly verified |
Full text not readStored summary read |
N21 · Evidence conditionAre shared reports and repeated attacks added as independent studies?Required |
The early paper and later registered results are shared by the parent's two subquestions. The 41 participants, 164 attacks and 209/189 are not calculated as independent participant totals, and registered results are not certified as a separate paper. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Two reports, shared subquestions and registered-result versions |
Material needed: Links among original trials, reports, sites, recruitment, participants and registration versions are needed. Unique trial, participant and independent-replication counts remain unverified. This records needed materials; no new research was executed. |
| 22 |
Partly verified |
Full text not readStored summary read |
N22 · Evidence conditionAre registration IDs and posting dates distinguished from current reading?Required |
The later NCT01770080, EudraCT 2011-004777-89 and results version 1 posting date 2025-05-22 are retained from the bibliography. The early pre-registration-era absence narrative is historical and does not represent current registration comparison. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
NCT01770080, EudraCT and posting of results version 1 |
Material needed: Actual original registration, plan, amendments and result-version materials are needed. The early record is not converted into a new registry-search conclusion, or a link into completed reading. This records needed materials; no new research was executed. |
| 23 |
Partly verified |
Full text not readStored summary read |
N23 · Evidence conditionAre selected D and parent D28, Caution and axes distinguished?Required |
The selected subquestion has D and lacks individual score, status and axes. Parent D28, Caution and axes remain parent context without filling a subclaim score. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Selected subclaim grade and absence of individual score, status and axes |
Material needed: Content review of the subquestion and parent boundary remains incomplete. No new grade, score, clinical status or certification of independence is created. This records needed materials; no new research was executed. |
| 24 |
Partly verified |
Full text not readStored summary read |
N24 · Evidence conditionAre stored-summary reading and external-original reading distinguished?Required |
The preserved parent summary was read for production. Historical bibliographic claims of verification, cross-checking, full-text reading and calculation remain historical; external abstracts, full text, registration, protocols and SAPs are unread. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Materials actually read, separated by type |
Material needed: External acquisition, reading and content review are separate events. A link does not establish original reading, accessibility or completed review. This records needed materials; no new research was executed. |
| 25 |
Partly verified |
Full text not readStored summary read |
N25 · Evidence conditionHow far do representative values in the Korean and English accounts apply?Required |
The parent's Korean and English accounts and representative values are preserved. Representative dose, population and endpoint summaries are not automatically applied as quantities, denominators or identical outcomes across every report, arm and endpoint. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Scope of language-specific accounts and representative formulation, population and endpoint |
Material needed: Original material comparing report-specific populations, formulations, comparators, endpoints, times and denominators is needed. No current comparison with external English originals or correction review was performed. This records needed materials; no new research was executed. |
| 26 |
Partly verified |
Full text not readStored summary read |
N26 · Evidence conditionAre the evidence date, empty correction history and production time distinguished?Required |
The original evidence date is 2026-09-07, with an empty correction array and deliberation text. Production time does not become an evidence-verification date and no nonexistent correction is created. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Original evidence date versus correction and change events |
Material needed: Material additions, criterion revisions, observation application and verdict changes must preserve the complete prior account and distinguish events, versions and reasons. This records needed materials; no new research was executed. |
| 27 |
Partly verified |
Full text not readStored summary read |
N27 · Evidence conditionDo report or material-slot counts represent unique trials or quality scores?Required |
Report links, stored summaries and external-material slots describe table structure. They are not acquired external papers, unique participants, original trials, independent replications or quality scores; shared material is not counted twice. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Table structure versus unique clinical units and actual reading |
Material needed: Original trial, report and cohort links, and actual acquisition and reading records, are needed. Unique trial and participant counts remain unverified. This records needed materials; no new research was executed. |
| 28 |
Partly verified |
Full text not readStored summary read |
N28 · Evidence conditionWhere should new material and corrections be linked?Required |
Original material, existing conditions and observations are preserved. New material must link to relevant comparisons, denominators, endpoints, reports and subquestion boundaries; this production is not labeled as new retrieval or a revised verdict. |
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval. |
Distinction between criterion revision, material updates and verdict changes |
Material needed: After acquisition and content review, the complete prior account must be preserved and events, versions and reasons recorded. No new procedures, treatment guidance or calculations are created. This records needed materials; no new research was executed. |